Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838903 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,049
- Enrollment target
- 20
- Study locations
NCT00838903: Completed Phase 3 study of Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.
NCT00838903 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,049 participants, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00838903, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,049 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Primary Outcome
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 104 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region. Difference of least squares means (albiglutide - placebo,
Conditions Studied
Interventions
- DRUG metformin
- BIOLOGICAL albiglutide
- DRUG sitagliptin
- DRUG glimepiride
- BIOLOGICAL placebo albiglutide
Study Locations (20)
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Gilbert
- GSK Investigational Site - Green Valley
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
- GSK Investigational Site - Tucson
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Dothan
- GSK Investigational Site - Hueytown
- GSK Investigational Site - Mobile
- GSK Investigational Site - Tuscaloosa
Arkansas
- GSK Investigational Site - Bull Shoals
- GSK Investigational Site - Harrisburg
- GSK Investigational Site - Hot Springs
- GSK Investigational Site - Jonesboro
- GSK Investigational Site - Searcy
California
- GSK Investigational Site - Buena Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,049 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
What the finished NCT00838903 record still lists
NCT00838903 is an interventional study that assigns participants to a tested intervention. Its 1,049 participants enrollment target places it among the larger protocols in the corpus, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 5 interventions - of which metformin is the first listed.
NCT00838903 names 20 study sites across 4 states, led by Arizona, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00838903 about?
NCT00838903 is a clinical study titled "Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes". The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
What is the current status of trial NCT00838903?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,049 participants. The study started on 2009-02. Estimated completion is 2013-04.
What conditions does trial NCT00838903 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00838903?
The interventions under investigation include: metformin (DRUG), albiglutide (BIOLOGICAL), sitagliptin (DRUG), glimepiride (DRUG), placebo albiglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00838903?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00838903 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00838903's enrollment target sits among peer trials
1,049 31st of 348 higher than 317 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
- NCT05915377 · 1,050 participants · NA
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia